14 research outputs found
What do Cochrane systematic reviews say about interventions for vitamin D supplementation?
Comprehensive core stability intervention and coordination of care in acute and subacute stroke rehabilitation—a pilot study
A survey to explore what information, advice and support community-dwelling people with stroke currently receive to manage instability and falls
Clinical features of fallers among inpatient subacute stroke: an observational cohort study
C. elegans FOG-3/Tob can either promote or inhibit germline proliferation, depending on gene dosage and genetic context
The Sound of Danger: Threat Sensitivity to Predator Vocalizations, Alarm Calls, and Novelty in Gulls
An assessment of randomized controlled trials (RCTs) for non-communicable diseases (NCDs): more and higher quality research is required in less developed countries
Research is crucial to implement evidence-based health interventions for control of non-communicable diseases (NCDs). This study aims to assess main features of randomized controlled trials (RCTs) for the control of NCDs, and to identify gaps in clinical research on NCDs between high-income and less developed countries. The study included 1177 RCTs in 82 Cochrane Systematic reviews (CSRs) and evaluated interventions for adults with hypertension, diabetes, stroke, or heart diseases. Multivariate logistic regression analyses were conducted to explore factors associated with risk of bias in the included RCTs. We found that 78.2% of RCTs of interventions for major NCDs recruited patients in high-income countries. The number of RCTs included in the CSRs was increasing over time, and the increasing speed was more noticeable for RCTs from middle-income countries. RCTs in less developed countries tended to be more recently published, less likely to be published in English, with smaller sample sizes, and at a higher risk of bias. In conclusion, there is still a lack of research evidence for control of NCDs in less developed countries. To brace for rising NCDs and avoid waste of scarce research resources, not only more but also higher quality clinical trials are required in low-and-middle-income countries